DaVita Inc
DVA: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|%D | LOCK|&#%R | LOCK|!@!>bD$ |
DaVita Continues to Use Share Repurchases to Boost Bottom-Line Growth
Business Strategy and Outlook
After selling DaVita Medical Group in 2019, DaVita focuses on providing services to end-stage renal disease, or ESRD, patients primarily in the United States, although its international footprint is expanding organically and through acquisitions. Over several decades, DaVita has built the largest network of dialysis clinics in the US, and although covid-19-related mortality and labor pressures cut into its profits in recent years, we see brighter days ahead for the firm, despite long-term potential challenges emerging related to the expansion of obesity drugs.
